What conditions count as a weight-related comorbidity for GLP-1 eligibility?

Why do comorbidities matter for GLP-1 eligibility?

Comorbidities matter because the FDA labels set two different entry points. Adults with obesity (a BMI of 30 or higher in the pivotal trials) were enrolled without any additional condition, while adults with overweight (BMI 27 to just under 30) needed at least one weight-related comorbid condition to participate. The current Wegovy and Zepbound labels carry that same structure in their indications: obesity alone, or overweight in the presence of at least one weight-related comorbid condition.

This is a criterion physicians apply, not a self-service checklist. Meeting a BMI number plus a diagnosis does not by itself mean a medication is appropriate. A licensed physician weighs the full picture, including contraindications like a personal or family history of medullary thyroid carcinoma, before prescribing.

Which conditions are named in the FDA labels?

Five conditions appear by name across the two labels' criteria. The Wegovy trials accepted treated or untreated dyslipidemia or hypertension as the qualifying condition. The Zepbound trials used a broader list: dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease. Type 2 diabetes was studied separately in both programs, in dedicated trials that enrolled adults with type 2 diabetes and a BMI of 27 or higher.

Two of these conditions have since become standalone indications. As of the 2025 label revisions, Zepbound is separately approved to treat moderate to severe obstructive sleep apnea in adults with obesity (approved December 2024), and Wegovy is separately approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

What other conditions do physicians consider weight-related?

Clinical practice recognizes a longer list than the label examples. The AACE and American College of Endocrinology obesity guidelines evaluate weight-related complications including prediabetes, metabolic syndrome, fatty liver disease (now called MASLD), polycystic ovary syndrome, osteoarthritis of weight-bearing joints, GERD, and obstructive sleep apnea, among others.

Physicians typically weigh these the same way: does the patient have a health problem that excess weight is causing or worsening, and would weight reduction plausibly improve it? That said, insurers and pharmacy benefit managers often use narrower definitions than clinicians do, so a condition a physician counts may not be one a particular insurance plan accepts for coverage purposes.

How is a comorbidity documented for a GLP-1 prescription?

Documentation usually means objective records rather than self-report. For hypertension, that is blood pressure readings or a current prescription. For dyslipidemia, a lipid panel. For type 2 diabetes or prediabetes, an HbA1c result. For obstructive sleep apnea, a sleep study; the Zepbound trials defined OSA severity by the apnea-hypopnea index measured on a polysomnogram. For cardiovascular disease, cardiology or hospital records.

In a telehealth visit, the physician reviews your medical history, current medications, and any lab work you can share. Recent labs make the evaluation faster and more accurate, and insurers frequently require documented evidence of the comorbidity before covering a GLP-1 at a BMI between 27 and 30. If you are unsure whether a condition in your history counts, raise it with the physician rather than ruling yourself out.

More questions, answered

Related questions